|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
MXPA06008700A
(es)
|
2004-02-06 |
2007-01-19 |
Morphosys Ag |
Anticuerpos anti-cd38 humanos y usos para los mismos.
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
WO2005103083A2
(en)
*
|
2004-02-06 |
2005-11-03 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
|
IL316252A
(en)
|
2005-03-23 |
2024-12-01 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
|
CA2625681C
(en)
*
|
2005-10-12 |
2016-08-02 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
|
|
SI1971366T1
(sl)
|
2005-12-29 |
2014-10-30 |
Janssen Biotech, Inc. |
Humana protitelesa anti-il-23, sestavki, postopki in uporabe
|
|
WO2007142241A1
(ja)
*
|
2006-06-05 |
2007-12-13 |
Hiroshima University |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
EP2081595B1
(en)
|
2006-09-26 |
2019-04-10 |
Genmab A/S |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
AU2013209322A1
(en)
*
|
2006-10-19 |
2013-08-15 |
Sanofi-Aventis |
Novel anti-cd38 antibodies for the treatment of cancer
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
PT2580243T
(pt)
|
2010-06-09 |
2020-01-22 |
Genmab As |
Anticorpos contra cd38 humana
|
|
US8877899B2
(en)
|
2010-09-27 |
2014-11-04 |
Morphosys Ag |
Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
|
|
TW201219568A
(en)
*
|
2010-10-05 |
2012-05-16 |
Daiichi Sankyo Co Ltd |
Antibody targeting osteoclast-related protein Siglec-15
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EA034989B1
(ru)
|
2011-10-28 |
2020-04-15 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
|
|
JP6426093B2
(ja)
|
2012-09-25 |
2018-11-28 |
モルフォシス・アーゲー |
組み合わせ及びその使用
|
|
ES2621377T3
(es)
|
2012-11-05 |
2017-07-03 |
Morphosys Ag |
Anticuerpo marcado radiactivamente y usos del mismo
|
|
JP2014117191A
(ja)
*
|
2012-12-13 |
2014-06-30 |
Fisheries Research Agency |
リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
WO2014178820A1
(en)
|
2013-04-29 |
2014-11-06 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
CN105873953A
(zh)
|
2013-11-04 |
2016-08-17 |
格兰马克药品股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
SI3122781T1
(sl)
*
|
2014-03-28 |
2020-03-31 |
Xencor, Inc. |
Bispecifična protitelesa, ki se vežejo na CD38 in CD3
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
EP3154581B1
(en)
|
2014-06-16 |
2019-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
CA3220466A1
(en)
|
2014-10-29 |
2016-05-06 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for mt1-mmp
|
|
JP6730271B2
(ja)
|
2014-10-29 |
2020-07-29 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
インターフェロンα２Ｂバリアント
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
EA037065B1
(ru)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Гетеродимерные антитела, связывающие cd3 и cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HUE055115T2
(hu)
|
2014-11-26 |
2021-10-28 |
Xencor Inc |
CD3-at és CD20-at kötõ heterodimer antitestek
|
|
US10793630B2
(en)
|
2014-12-04 |
2020-10-06 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
WO2016164669A2
(en)
|
2015-04-08 |
2016-10-13 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
|
PT3294769T
(pt)
|
2015-05-13 |
2021-04-13 |
Morphosys Ag |
Tratamento para mieloma múltiplo (mm)
|
|
KR102602754B1
(ko)
|
2015-05-20 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
PE20181323A1
(es)
|
2015-06-22 |
2018-08-14 |
Janssen Biotech Inc |
Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
|
|
PT3313441T
(pt)
|
2015-06-24 |
2024-05-07 |
Janssen Biotech Inc |
Modulação imunitária e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
BR112018008901A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
formulações subcutâneas de anticorpos anti-cd 38 e seus usos
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
JP7362250B2
(ja)
|
2016-03-04 |
2023-10-17 |
モルフォシス・アーゲー |
多発性骨髄腫におけるｍタンパク質反応の臨床評価
|
|
AU2017290086A1
(en)
|
2016-06-28 |
2019-01-24 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
JP2019521171A
(ja)
|
2016-07-20 |
2019-07-25 |
ヒブリジェニクス・エスアー |
抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
|
|
NZ759835A
(en)
|
2017-06-08 |
2025-09-26 |
Black Belt Therapeutics Ltd |
Cd38 modulating antibody
|
|
KR102719065B1
(ko)
|
2017-06-08 |
2024-10-17 |
블랙 벨트 테라퓨틱스 리미티드 |
Cd38 조정 항체
|
|
CN110997009B
(zh)
|
2017-06-20 |
2025-01-21 |
索伦托药业有限公司 |
Cd38抗体药物缀合物
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
US11261214B2
(en)
|
2017-08-04 |
2022-03-01 |
Bicycletx Limited |
Bicyclic peptide ligand specific for CD137
|
|
JP7299873B2
(ja)
|
2017-08-16 |
2023-06-28 |
ブラック ベルト セラピューティクス リミテッド |
Ｃｄ３８抗体
|
|
US11542338B2
(en)
|
2017-08-16 |
2023-01-03 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
WO2019034752A1
(en)
|
2017-08-16 |
2019-02-21 |
Tusk Therapeutics Ltd |
CD38 MODULATOR ANTIBODY
|
|
CN120058939A
(zh)
*
|
2017-10-10 |
2025-05-30 |
赛诺菲 |
抗cd38抗体及与抗cd3和抗cd28抗体的组合
|
|
WO2019089832A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
EP3694546A1
(en)
|
2018-01-30 |
2020-08-19 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN110144008B
(zh)
*
|
2018-02-12 |
2021-03-19 |
杭州尚健生物技术有限公司 |
Cd38蛋白抗体及其应用
|
|
MX2020008791A
(es)
|
2018-02-23 |
2021-01-08 |
Bicycletx Ltd |
Ligandos de peptidos biciclicos multimericos.
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
GB201810320D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to CD38
|
|
BR112021007227A2
(pt)
|
2018-10-17 |
2021-08-10 |
Janssen Biotech, Inc. |
método para fornecer administração subcutânea de anticorpos anti-cd38
|
|
CA3120237A1
(en)
|
2018-11-20 |
2020-05-28 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il-23 specific antibody
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
MX2021007047A
(es)
|
2018-12-14 |
2021-10-26 |
Morphosys Ag |
Formulaciones de anticuerpos.
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
GB201900530D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for CD38
|
|
KR20220002891A
(ko)
|
2019-03-15 |
2022-01-07 |
모르포시스 아게 |
자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
|
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
|
PH12021553254A1
(en)
|
2019-06-27 |
2022-09-19 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
WO2021003432A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US20240228592A1
(en)
*
|
2020-03-31 |
2024-07-11 |
Bio-Thera Solutions, Ltd. |
Antibody and fusion protein for treating coronaviruses and use thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
IL298389A
(en)
|
2020-05-21 |
2023-01-01 |
Janssen Biotech Inc |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
WO2021260657A1
(en)
|
2020-06-26 |
2021-12-30 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CN114075283A
(zh)
*
|
2020-08-12 |
2022-02-22 |
三生国健药业（上海）股份有限公司 |
结合人cd38的抗体、其制备方法和用途
|
|
CN114195893A
(zh)
*
|
2020-09-17 |
2022-03-18 |
百奥泰生物制药股份有限公司 |
抗整联蛋白抗体或抗原结合片段及其应用
|
|
GB202016331D0
(en)
|
2020-10-15 |
2020-12-02 |
Bicyclerd Ltd |
Bicyclic peptide ligand drug conjugates
|
|
WO2022137186A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
|
US20240109977A1
(en)
|
2021-01-14 |
2024-04-04 |
Morphosys Ag |
Anti-cd38 antibodies and their uses
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
MX2023010499A
(es)
|
2021-03-09 |
2023-09-18 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cldn6.
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
WO2022238963A2
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating solid tumors
|
|
TW202310870A
(zh)
|
2021-05-12 |
2023-03-16 |
瑞士商Ｃｒｉｓｐｒ治療公司 |
用於治療造血惡性腫瘤之靶向ｃｄ７０的基因工程化免疫細胞
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|
|
EP4426435A1
(en)
|
2021-11-03 |
2024-09-11 |
Janssen Biotech, Inc. |
Corticosteriod reduction in treatment with anti-cd38 antibodies
|
|
WO2023098813A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Nanjing Leads Biolabs Co., Ltd. |
Antibodies binding cd38 and uses thereof
|
|
EP4472740A1
(en)
|
2022-01-31 |
2024-12-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|